You are viewing the site in preview mode
Skip to main content
|
Body size measurement
| |
ER+ tumors
| | |
ER– tumors
| |
|---|
|
p-mTOR overexpressed cases vs controls
|
p-mTOR negative/low cases vs controls
|
P-heterogeneity
|
p-mTOR overexpressed cases vs controls
|
p-mTOR negative/low cases vs controls
|
P-heterogeneity
|
|---|
|
OR (95% CI)
|
OR (95% CI)
| |
OR (95% CI)
|
OR (95% CI)
| |
|---|
|
BMI, kg/m2
|
|
No. of cases/no. of controls
|
164/1973
|
309/1973
| |
25/1973
|
211/1973
| |
|
< 25
|
1.00 [reference]
|
1.00 [reference]
| |
1.00 [reference]
|
1.00 [reference]
| |
|
25–29.99
|
1.29 (0.77–2.16)
|
1.02 (0.72–1.45)
| |
0.83 (0.23–2.99)
|
1.00 (0.68–1.49)
| |
|
30–34.99
|
1.48 (0.87–2.52)
|
1.33 (0.92–1.91)
| |
1.72 (0.54–5.48)
|
0.84 (0.54–1.31)
| |
|
≥ 35
|
1.39 (0.82–2.34)
|
0.75 (0.51–1.11)
|
0.015
|
0.90 (0.25–3.25)
|
0.61 (0.39–0.96)
|
0.09
|
|
P-trend
|
0.27
|
0.18
| |
0.97
|
0.015
| |
|
WC
|
|
No. of cases/no. of controls
|
162/1955
|
304/1955
| |
25/1955
|
206/1955
| |
|
Q1
|
1.00 [reference]
|
1.00 [reference]
| |
1.00 [reference]
|
1.00 [reference]
| |
|
Q2
|
1.65 (0.90–3.01)
|
1.09 (0.74–1.60)
| |
1.81 (0.32–10.1)
|
1.09 (0.70–1.70)
| |
|
Q3
|
2.28 (1.28–4.06)
|
1.36 (0.93–1.98)
| |
4.70 (1.00–22.07)
|
1.04 (0.57–1.63)
| |
|
Q4
|
1.93 (1.06–3.51)
|
1.01 (0.67–1.50)
|
0.26
|
2.60 (0.50–13.6)
|
0.83 (0.52–1.32)
|
0.55
|
|
P-trend
|
0.050
|
0.97
| |
0.25
|
0.31
| |
|
WHR
|
|
No. of cases/no. of controls
|
162/1955
|
304/1955
| |
25/1955
|
206/1955
| |
|
Q1
|
1.00 [reference]
|
1.00 [reference]
| |
1.00 [reference]
|
1.00 [reference]
| |
|
Q2
|
1.17 (0.57–2.04)
|
1.34 (0.91–1.98)
| |
1.58 (0.26–9.59)
|
1.34 (0.85–2.10)
| |
|
Q3
|
1.54 (0.91–2.60)
|
1.47 (1.00–2.15)
| |
5.35 (1.16–24.71)
|
1.28 (0.80–2.03)
| |
|
Q4
|
1.69 (1.01–2.84)
|
1.37 (0.93–2.03)
|
0.36
|
3.42 (0.68–17.16)
|
1.60 (0.99–2.58)
|
0.89
|
|
P-trend
|
0.027
|
0.14
| |
0.08
|
0.38
| |
- Abbreviations: BMI body mass index, ER estrogen receptor, OR odds ratio, Q quartile, WC waist circumference, WHR waist-to-hip ratio
- Models adjusted for age, race, family history of breast cancer, menopausal status, age of menarche, parity, history of breastfeeding, oral contraceptive use, and history of diabetes
